Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease

Renal Failure

Volumn 36, Issue 4, 2014, Pages 613-618

  Boban, Milojkovic ^a   Kocic, Gordana ^a   Radenkovic, Sonja ^b   Pavlovic, Radmila ^a   Cvetkovic, Tatjana ^a   Deljanin Ilic, Marina ^c   Ilic, Stevan ^c   Bobana, Milojkovic D ^d   Djindjic, Boris ^b   Stojanovic, Dijana ^b   Sokolovic, Dusan ^a   Jevtovic Stoimenov, Tatjana ^a  

^a Ni University Medical Faculty   (Serbia)

^b Department of Pathophysiology ^*  (United States)

^c Institute for Cardiology Niska Banja Medical Faculty   (Serbia)

^d UNIVERSITY OF NI   (Serbia)

Author keywords

ADP; AMP; ATP; Circulating purine nucleotides; Dialysis; Essential hypertension; Renal failure; Xanthine dehydrogenase; Xanthine oxidase

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; PURINE DERIVATIVE; PURINE NUCLEOTIDE; REACTIVE OXYGEN METABOLITE; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; ADENOSINE TRIPHOSPHATE; CREATININE; UREA;

ADULT; ARTICLE; CATABOLISM; CONTROLLED STUDY; DEGRADATION; DIALYSIS; DISEASE COURSE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; BLOOD PRESSURE; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ADENINE NUCLEOTIDES; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS; UREA; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 84898929685     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.882240     Document Type: Article

References (48)

1. Rostand SG. Is renal failure caused by primary hypertension? Why does the controversy continue? Nephrol Dial Transpl. 1998; 13:3007-3010
2. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage. Implications for therapy. Hypertension. 2004;44:595-601
3. Madhaven S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet. 1995;345:749-751
4. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989; 320:684-688
5. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int. 1990;37:1113-1119
6. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Johnson RJ. A single pathway for the development of essential hypertension. Cardiol Rev. 2003;11: 180-196
7. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000. A rising tide. Hypertension. 2004;44:398-404
8. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2-7
9. Johnson R, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? JASN. 2005;16(7):1909-1919
10. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106
11. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67: 237-247
12. Pearson JD, Gordon JL. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature. 1979;281:384-386
13. Gordon JL. Extracellular ATP: effects, sources and fate. Biochem J. 1986;233:309-319
14. Borst M, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res. 1991;68:797-806
15. Coade S, Pearson J. Metabolism of adenine nucleotides in human blood. Circ Res. 1989;65:531-537
16. Vial C, Owen P, Opie LH, Posel D. Significance of release of adenosine triphosphate and adenosine induced by hypoxia or adrenaline in perfused rat heart. J Mol Cell Cardiol. 1987;19: 187-197
17. Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res. 1992;26:40-47
18. Bodin P, Burnstock G. ATP-stimulated release of ATP by human endothelial cells. J Cardiovasc Pharmacol. 1996;27:872-875
19. Beigi R, Kobatake E, Aizawa M, Dubyak GR. Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol. 1999;276:C267-C278
20. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res. 1998;47:351-354
21. Schwiebert LM, Rice WC, Kudlow BA, Taylor AL, Schwiebert EM. Extracellular ATP signaling and P2X nucleotide receptors in monolayers of primary human vascular endothelial cells. Am J Physiol. 2002;282:C289-C301
22. North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013-1067
23. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-492
24. Darius H, Stahl GL, Lefer AM. Pharmacological modulation of ATP release from isolated rat hearts in response to vasoconstrictor stimuli using a continuous flow technique. J Pharmacol Exp Ther. 1987;240:542-547
25. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;16;555(Pt 3):589-606
26. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114
27. Zhang Z, Blake DR, Stevens CR, et al. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res. 1998; 28(2):151-164
28. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003; 107(10):1383-1389
29. de Jong JW, Schoemaker RG, de Jonge R, et al. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;32(11):2083-2089
30. Pfeffer KD, Huecksteadt TP, Hoidal JR. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation. J Immunol. 1994; 153(4):1789-1797
31. National Kidney Foundation-K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(suppl. 1):S1-S266
32. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC VI). Arch Intern Med. 1997; 157:2413-2446
33. Coolen E, Arts I, Swennen E, Bast A, Cohen Stuart M, Dagnelie P. Simultaneous determination of adenosine triphosphate and its metabolites in human whole blood by RP-HPLC and UV-detection. J Chromatogr B. 2008;64:43-51
34. Kizaki H, Sakurada T. Simple micro-assay methods for enzymes of purine metabolism. J Lab Clin Med. 1977;89(5):1135-1144
35. Perneger TV, Nieto J, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine. Results from the "Clue" study and the ARIC study. JAMA. 1993; 269:488-493
36. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 25,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2394-2441
37. Lindeman RD, Tobin JD, Shock NW. Hypertension and the kidney. Nephron. 1989;47(Suppl. 1):62-67
38. Goldbeter A. Modulation of the adenylate energy charge by sustained metabolic oscillations. FEBS Lett. 1974;43(3):327-330
39. Tykarski A, G?uszek J, Banaszak F. Value of oxypurines and uric acid in plasma, renal excretion of oxypurines and uric acid as well as plasma adenosine deaminase and AMP deaminase activity in patients with essential hypertension. Pol Arch Med Wewn. 1993; 89(3):223-229
40. Kinugawa T, Ogino K, Osaki S, et al. Altered purine nucleotide degradation during exercise in patients with essential hypertension. Metabolism. 2001;50(6):646-650
41. Romero JC, Reckelhoff JF. State-of-the-Art lecture: role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999;34:943-949
42. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-360
43. Johnson RJ, Srinivas T, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005;25:3-8
44. Graham A, McLees A, Kennedy C, Gould GW, Plevin R. Stimulation by the nucleotides, ATP and UTP of mitogen-activated protein kinase in EAhy 926 endothelial cells. Br J Pharmacol. 1996;117:1341-1347
45. Kolosova IA, Mirzapoiazova T, Adyshev D, et al. Signaling pathways involved in adenosine triphosphate-induced endothelial cell barrier enhancement. Circ Res. 2005;97:115-124
46. Patel V, Brown C, Goodwin A, Wilkie N, Boarder MR. Phosphorylation and activation of p42 and p44 mitogen-activated protein kinase are required for the P2 purinoceptor stimulation of endothelial prostacyclin production. Biochem J. 1996;320:221-226
47. Bogatcheva NV, Dudek SM, Garcia JG, Verin AD. Mitogenactivated protein kinases in endothelial pathophysiology. J Investig Med. 2003;51:341-352
48. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37:541-546.